{Reference Type}: Journal Article
{Title}: Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study.
{Author}: Nishikawa N;Hatano T;Nishioka K;Ueno SI;Saiki S;Nakamura R;Yoritaka A;Ogawa T;Shimo Y;Sako W;Shimura H;Furukawa Y;Kamei T;Ishida T;Hattori N; ;
{Journal}: J Neurol Sci
{Volume}: 461
{Issue}: 0
{Year}: 2024 Jun 15
{Factor}: 4.553
{DOI}: 10.1016/j.jns.2024.123051
{Abstract}: <B>BACKGROUND: </B>Safinamide is an effective adjunctive therapy for wearing-off in Parkinson's disease (PD); however, evidence is lacking in older patients and those in the early stages of wearing-off. This study evaluated the efficacy and safety of safinamide as adjunctive therapy in patients with PD treated with levodopa monotherapy in clinical practice.<BR><B>METHODS: </B>This multicentre, open-label observational study was conducted at five sites in Japan. Patients diagnosed with PD and wearing-off initiated safinamide as adjunctive therapy with levodopa monotherapy. Efficacy endpoints were mean changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I, III, and IV scores; daily ON-time without dyskinesia using 24-h patient symptom diaries; and 39-item Parkinson's Disease Questionnaire (PDQ-39) scores at 18 weeks of treatment.<BR><B>RESULTS: </B>In total, 24 patients initiated safinamide (66.7% were aged ≥75 years); the mean duration of wearing-off was 1.2 years. MDS-UPDRS Part III total score, Part IV total score, and PDQ-39 summary index decreased significantly from baseline (mean change -7.0 [p = 0.012], -2.4 [p = 0.007] and - 5.3 [p = 0.012], respectively). There was a non-statistically significant increase of 1.55 h in mean daily ON-time without dyskinesia. Numerical Rating Scale total score for pain (p = 0.015), and scores for OFF-period pain (p = 0.012) and nocturnal pain (p = 0.021) subdomains were significantly improved in the subgroup with pain. Most reported adverse events were classified as mild.<BR><B>CONCLUSIONS: </B>Safinamide improved motor and non-motor symptoms and quality of life-related measures in older patients with PD in the early stages of wearing-off without new safety concerns.<BR><B>BACKGROUND: </B>University Hospital Medical Information Network in Japan; study ID: UMIN000044341.